<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
BOVIE MEDICAL CORPORATION (f/k/a AN-CON GENETICS, INC.)
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
10211F100
--------------
(CUSIP Number)
Mr. Eric Rainer Bashford Irwin A. Kishner, Esq.
c/o Herrick, Feinstein, LLP Herrick, Feinstein LLP
2 Park Avenue 2 Park Avenue
New York, New York 10016 New York, New York 10016
Tel.: (212) 592-1400 Tel.: (212) 592-1400
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
March 10, 1999
------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box. [ ]
Check the following box if a fee is being paid with the statement. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filed out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
Page 1 of 3 Pages
<PAGE>
_______________________________________________________________________________
CUSIP No. 10211F100 13D Page 2 of 3 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Eric Rainer Bashford Charitable Remainder Unitrust
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 980,000 shares of Common Stock
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | |
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 980,000 shares of Common Stock
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| |
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
980,000 shares of Common Stock
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.6%
______________________________________________________________________________
14 TYPE OF REPORTING PERSON*
______________________________________________________________________________
* SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
<PAGE>
PART II TO SCHEDULE 13D
This statement constitutes Amendment No. 1 to the statement on Schedule 13D
filed with the Securities and Exchange Commission on February 19, 1998 (the
"Original Statement"). All defined terms hereunder have the meanings set forth
in the Original Statement. This Amendment No. 1 reflects certain material
changes in the information set forth in the Original Statement, as follows:
Item 1. Security and Issuer
Shares of Common Stock
Bovie Medical Corporation (f/k/a An-Con Genetics, Inc.)
734 Walt Whitman Road
Suite 207
Melville, New York 11747
(hereinafter, the "Issuer")
Item 5. Interest in Securities of the Issuer
(a) The Trust is the beneficial owner of 980,000 shares
of Common Stock of the Issuer. The total number of
outstanding shares of the Issuer's Common Stock is
14,629,693. As of March 10, 1999 the Trust owns 6.6%
of the Issuer's Common Stock.
(c) On March 10, 1999, the Trust sold 145,000 shares of
Common Stock of the Issuer in the market pursuant to
Rule 144 for $0.58982 price per share.
SIGNATURE
---------
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
March 25, 1999 By: /s/ Eric Rainer Bashford
- ----------------- ---------------------------
Date Signature
Name: Eric Rainer Bashford
